06:14 AM EDT, 07/23/2024 (MT Newswires) -- MAIA Biotechnology ( MAIA ) said Tuesday that a combination of THIO and cemiplimab was well tolerated in patients with advanced non-small cell lung cancer in a phase 2 trial.

Results of the trial showed the safety, efficacy and ongoing benefit of the oncology therapy, the company said.

Six patients remain on treatment after more than 12 months of therapy, according to the company.

Price: 4.4000, Change: +0.65, Percent Change: +17.33